Welcome to our dedicated page for Castle Biosciences SEC filings (Ticker: CSTL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Castle Biosciences, Inc. (CSTL) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a Nasdaq-listed issuer. Castle Biosciences files reports with the U.S. Securities and Exchange Commission that cover its financial performance, governance changes, risk factors and material events related to its molecular diagnostics business in dermatologic and gastroenterological disease.
Investors can review current reports on Form 8-K, where Castle discloses items such as quarterly financial results, updated revenue guidance, the release of investor presentations and amendments to its bylaws. For example, 8-K filings describe when the company announces earnings for periods such as the quarter ended September 30, 2025, or when its board adopts amended and restated bylaws addressing stockholder meetings, director nominations, voting standards and indemnification provisions.
Alongside 8-Ks, users can access annual reports on Form 10-K and quarterly reports on Form 10-Q (when available in the SEC feed). These filings typically contain audited or reviewed financial statements, management’s discussion and analysis of results, details on Castle’s test portfolio, information about markets served and disclosures about risks associated with its diagnostics operations.
For those monitoring governance and capital structure, the SEC filings also identify Castle Biosciences’ state of incorporation (Delaware), the class of securities registered (common stock, $0.001 par value per share) and its listing on The Nasdaq Global Market under the symbol CSTL.
Stock Titan enhances this raw filing data with AI-powered summaries that explain key points in accessible language. Users can quickly see the main themes of a lengthy 10-K or 10-Q, identify notable changes in guidance or governance reported in 8-Ks, and navigate directly to sections that matter most for understanding Castle Biosciences’ molecular diagnostics business.
Castle Biosciences' Chief Commercial Officer reported equity transactions involving restricted stock units and common stock. On December 9, 2025 and December 10, 2025, the reporting person acquired 15,961 and 6,170 shares of common stock coded "M" in connection with restricted stock units, and disposed of 6,441 and 2,490 shares coded "F" at prices of $38.25 and $38.02 per share.
After these transactions, the officer beneficially owned 100,025 shares of Castle Biosciences common stock directly. The filing also shows 15,961 restricted stock units outstanding from a grant made on December 9, 2022 that vests in four equal installments beginning on December 9, 2023, and notes that 24,679 restricted stock units granted on December 10, 2021 vest in four equal installments beginning on December 10, 2022. The ownership total includes 2,230 shares that were previously held by a family revocable trust and were distributed to the reporting person on February 5, 2025.
Castle Biosciences Inc. reported an insider stock sale by a director who also serves as president and chief executive officer. On December 4, 2025, the insider sold 1,339 shares of common stock at a weighted-average price of $40.03 per share in a transaction made under a contract, instruction or written plan intended to satisfy Rule 10b5-1(c), which was adopted on May 8, 2025.
After this sale, the insider directly owned 37,547 shares of Castle Biosciences common stock and reported additional indirect holdings through several family trusts, including 52,923 shares held by The Maetzold Descendants 2020 Trust and 44,986 shares held by the Derek Maetzold 2020 Irrevocable Trust.
Castle Biosciences, Inc. reported an insider stock sale by a senior executive. The company’s president and chief executive officer, who is also a director, filed a Form 4 showing the sale of 5,115 shares of common stock on 11/25/2025 at a weighted-average price of $40.049 per share.
The filing states that this transaction was made under a pre-arranged Rule 10b5-1 trading plan adopted on May 8, 2025. Following the sale, the executive directly owns 45,822 shares of Castle Biosciences common stock. In addition, the executive reports indirect ownership through several family and grantor retained annuity trusts, including 52,923 shares held by The Maetzold Descendants 2020 Trust and 85,959 shares held by DJM Grantor Retained Annuity Trust No. 5, among other trust holdings.
Castle Biosciences (CSTL) reported insider activity by its Chief Commercial Officer. On 11/20/2025, the officer exercised a stock option to buy 4,693 shares of common stock at $3.38 per share and on the same day sold 4,693 shares in open-market transactions at a weighted-average price of $35.58, with individual trades ranging from $35.40 to $35.85. These trades were carried out under a Rule 10b5-1 trading plan adopted on September 11, 2024.
After the transactions and a 68-share reconciliation adjustment, the officer beneficially owns 84,595 shares directly and 2,230 shares indirectly through a family revocable trust. The officer also holds 11,210 fully vested stock options with a $3.38 exercise price expiring on March 12, 2029.
Castle Biosciences Inc. insider trading report: A reporting person who serves as a director and as President & Chief Executive Officer of Castle Biosciences (CSTL) sold 2,678 shares of common stock on 11/18/2025 at a weighted-average price of
Castle Biosciences (CSTL) reported insider transactions by its Chief Commercial Officer on an amended Form 4. On 11/11/2025, the officer exercised stock options at $3.38 and sold 500 shares at a weighted-average sale price of $35.39. On 11/12/2025, the officer exercised options at $3.38 and sold 200 shares at $35.40. These trades were made under a Rule 10b5-1 plan adopted on September 11, 2024.
Following the transactions, beneficial ownership was 84,527 shares direct and 2,230 shares indirect held by a family revocable trust. Derivative securities beneficially owned after the reported transactions were 15,903 stock options expiring on 03/12/2029. The amendment notes the option exercises were inadvertently omitted from the original filing and are now reported.
Castle Biosciences (CSTL) Form 4: Chief Financial Officer Frank Stokes reported an open-market sale of 5,388 shares of common stock on 11/11/2025 at a weighted-average price of $35.08. The filing notes multiple trades executed between $34.44 and $35.37. Following the transaction, Stokes beneficially owns 43,328 shares, held directly. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on 08/12/2025.
Castle Biosciences (CSTL) reported an insider transaction by its Chief Commercial Officer on Form 4. The officer sold 500 shares of common stock on 11/11/2025 at a weighted-average price of $35.39 pursuant to a Rule 10b5-1 plan adopted on September 11, 2024. A separate sale of 200 shares occurred on 11/12/2025 at $35.40.
Following these transactions, the officer reported 84,027 shares held directly. In addition, 2,230 shares are held indirectly by the Tobin W and Susan M Juvenal Family Revocable Trust, of which the officer and spouse are trustees and beneficiaries include the officer, spouse, and their children.
Castle Biosciences (CSTL) reported an insider transaction by its Chief Operating Officer. On November 11, 2025, the COO sold 18,932 shares of common stock (code S) under a Rule 10b5-1 plan adopted on March 6, 2025 at a $35.10 weighted-average price, with trade prices ranging from $35.00 to $35.37.
Following the transactions, the reporting person beneficially owns 12,323 shares directly and 97,251 shares indirectly via The Fritz Shorter Trust. The filing also notes a transfer of 3,686 shares from the trust to direct holdings on November 11, 2025.
Castle Biosciences (CSTL) reported insider transactions by President & CEO and Director Derek Maetzold. Under a Rule 10b5-1 plan adopted on May 8, 2025, he sold 6,458 shares on 11/04/2025 at a weighted-average price of $30.413, 237 shares on 11/04/2025 at $31.117, and 2,678 shares on 11/05/2025 at $31.851.
Following these sales, he held 53,615 shares directly. He also reports indirect holdings through family trusts, including 85,959 shares in DJM Grantor Retained Annuity Trust No. 5.
FAQ
What is the current stock price of Castle Biosciences (CSTL)?
What is the market cap of Castle Biosciences (CSTL)?
